Efficacy and Clinicogenomic Correlates of Response to Immune Checkpoint Inhibitors Alone or with Chemotherapy in Non-Small Cell Lung Cancer
Nature communications(2023)SCI 1区
Univ Texas MD Anderson Canc Ctr | Department of Imaging Physics | Division of Hematology and Oncology | Department of Biostatistics | Department of Radiology | Department of Radiation Oncology | Department of Thoracic Imaging | Department of Pathology | Department of Medicine
Abstract
The role of combination chemotherapy with immune checkpoint inhibitors (ICI) (ICI-chemo) over ICI monotherapy (ICI-mono) in non-small cell lung cancer (NSCLC) remains underexplored. In this retrospective study of 1133 NSCLC patients, treatment with ICI-mono vs ICI-chemo associate with higher rates of early progression, but similar long-term progression-free and overall survival. Sequential vs concurrent ICI and chemotherapy have similar long-term survival, suggesting no synergism from combination therapy. Integrative modeling identified PD-L1, disease burden (Stage IVb; liver metastases), and STK11 and JAK2 alterations as features associate with a higher likelihood of early progression on ICI-mono. CDKN2A alterations associate with worse long-term outcomes in ICI-chemo patients. These results are validated in independent external ( n = 89) and internal ( n = 393) cohorts. This real-world study suggests that ICI-chemo may protect against early progression but does not influence overall survival, and nominates features that identify those patients at risk for early progression who may maximally benefit from ICI-chemo.
MoreTranslated text
Key words
Cancer immunotherapy,Chemotherapy,Non-small-cell lung cancer,Science,Humanities and Social Sciences,multidisciplinary
PDF
View via Publisher
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
- Pretraining has recently greatly promoted the development of natural language processing (NLP)
- We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
- We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
- The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
- Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Try using models to generate summary,it takes about 60s
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Related Papers
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2023
被引用17
CANCERS 2023
被引用1
PATTERNS 2023
被引用4
Research Progress Related to Immunotherapy for Liver Metastasis of Non-Small Cell Lung Cancer
Advances in Clinical Medicine 2023
被引用0
Lung Cancer 2023
被引用2
PHARMACOLOGICAL RESEARCH 2023
被引用1
Adeno-to-squamous Transition Drives Resistance to KRAS Inhibition in LKB1 Mutant Lung Cancer
CANCER CELL 2024
被引用3
Cancers 2023
被引用1
MOLECULAR THERAPY ONCOLYTICS 2023
被引用1
Translational Lung Cancer Research 2023
被引用0
INTERNATIONAL IMMUNOPHARMACOLOGY 2024
被引用0
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper
去 AI 文献库 对话